Evalueserve
DECEMBER 6, 2021
On the other hand, Biotech heavily underperformed post Q1’21 primarily due to the shifting of focus towards cyclicals and negative sentiments arising as of result of greater regulatory clampdown on transformative deals and drug pricing. These companies will be able to reshape the competitive landscape of the pharmaceutical industry.
Alpha Sense BI
MAY 5, 2023
2023 so far has revealed ideal conditions for dealmaking due to valuation resets, lessened competition for deals, and new assets coming to market. Three years later, despite macroeconomic uncertainties, investors remain attracted to this space, particularly the more innovative and tech-influenced sub-sectors like biotech and MedTech.
Alpha Sense BI
MARCH 28, 2023
Third Bridges recognizes its shortcomings in its offerings—if you’re facing a unique business problem that has no pre-existing content offering potential solutions, you can take advantage of Third Bridge Forum or Connections. Who uses expert networks?
Expert insights. Personalized for you.
98 
Let's personalize your content